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ABSTRACT
Objectives: Increased rates of illicit drug inhalation
are thought to expose opiate misusers (OMUs) to an
enhanced risk of respiratory health problems. This pilot
study aimed to determine the feasibility of undertaking
respiratory screening of OMUs in a community clinic.
Setting: Single-centre UK community substance
misuse clinic.
Participants: All clinic attendees receiving treatment
for opiate misuse were eligible to participate. 36
participants (mean age=37) were recruited over a
5-week period. The sample included 26 males and
10 females.
Outcome measures: Spirometry without
bronchodilation; health related quality of life EQ-5D-3L;
Asthma Control Test; Mini Asthma Quality of Life;
Clinical COPD Questionnaire and the Treatment
Outcome Profile were used to assess the respiratory
health of participants. Findings were discussed with
staff and service users in 2 patient and public
involvement events and feedback was analysed
thematically.
Results: 34 participants reported that they had
smoked heroin. 8 participants diagnosed with asthma,
scored under 13 on the Asthma Control Test,
suggesting poorly controlled asthma. Participants
(n=28), without a diagnosis of asthma completed the
Lung Function Questionnaire. Of these, 79% produced
scores under 18, indicating symptoms associated with
the development of chronic obstructive pulmonary
disease. Spirometry showed 14% of all participants
had forced expiratory volume in 1 s/forced vital
capacity <0.7 (without bronchodilator), indicating
potential obstructive lung disease. Feedback from
service users and staff suggested a willingness and
capacity to deliver respiratory health screening
programmes. Insight towards the difficulties service
users have in accessing services and the burden of
respiratory health was also provided.
Conclusions: It is feasible to undertake respiratory
health screening of OMUs in a community clinic.
Larger screening studies are warranted to determine
the prevalence of respiratory health problems in this
population. Research regarding asthma medicines
adherence and access to healthcare among OMUs is
also required.
BACKGROUND
Owing to the potential consequences of
injecting behaviours, such as bloodborne
virus transmission (chronic liver disease,
HIV/AIDS) and venous ulceration post-
venous thromboembolism (VTE), there was a
gradual increase in the inhalation of opiates
from the early 1990s. Although there is a
paucity of evidence regarding rates of opiate
inhalation in recent years, it has been
reported that by the late 1990s, this was the
most frequent form of opiate use.1 However,
there are now growing concerns over the
Strengths and limitations of this study
▪ Owing to the small sample size, the quantitative
findings from this pilot study, in relation to the
prevalence of poor respiratory health in this
population, have to be approached with caution.
▪ Integrated patient and public involvement feed-
back allowed exploration of the burden of
respiratory disease in this population, the bar-
riers to respiratory care and potential solutions
for how to overcome these barriers from a
service user and practitioner perspective.
▪ This study investigated the contribution of
asthma control to poor respiratory health in
opiate misusers through the use of validated
self-report measures.
▪ There is an ongoing debate over the appropriate-
ness of the use of the Lung Function
Questionnaire (LFQ) and spirometry testing as
population screening tools for chronic obstruct-
ive pulmonary disease.
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impact the inhalation of opiates may have on an indivi-
dual’s respiratory health. For example, there is evidence
that heroin inhalation can trigger asthma exacerba-
tions2–4 and ﬁndings from the UK Review of Asthma
Deaths (2014) show that substance misuse was impli-
cated in 6% of deaths.5
Inhalation of opiates has been linked to early-onset
chronic obstructive pulmonary disease (COPD),6 which
is the ﬁfth biggest killer in the UK.7 Furthermore,
two-thirds of those affected by COPD are thought to be
undiagnosed.8 The independent effects of heroin inhal-
ation on the development of COPD remain difﬁcult to
determine from previous research, due to a failure to
control for tobacco smoking, which is also highly preva-
lent in this population.6 However, opiate misusers
(OMUs) remain a high-risk group, and the contribution
of circulatory and respiratory disease to premature mor-
tality of among opioid misusers in England has been
recently highlighted.9 In this study, data from a cohort
of 198 247 OMUs suggested that respiratory system dis-
eases accounted for 7% of all deaths in this population.
A recent screening study across three UK Crime
Reduction Initiative (CRI) services, also demonstrated a
high prevalence of COPD in relation to opiate inhal-
ation, with ﬁndings from spirometry testing suggesting
that a minimum of 28% of current or former heroin
smokers demonstrated evidence of airﬂow obstruction
consistent with COPD. It was also reported that COPD
was present in service users at a relatively young age.
The authors concluded that the screening of respiratory
health of OMUs in community services should be
explored further.10
Research has suggested that OMUs often fail to
engage with primary care services and display an over-
reliance on emergency departments,11 contributing to a
signiﬁcant economic burden on healthcare systems.12
Factors such as early-onset drug/alcohol-related cogni-
tive impairment, treatment concordance and poor social
support compound the difﬁculty in optimising proactive
medical care for OMUs.13 Further research exploring
the potential beneﬁt of screening programmes targeting
high-risk groups is advocated through current guidelines
proposing that the early diagnosis of COPD can signiﬁ-
cantly slow lung function decline and increase the dur-
ation a person can experience an active lifestyle.14
The aim of the current study was to determine the
prevalence of diagnosed and undiagnosed respiratory
health problems and feasibility of undertaking respiratory
screening of OMUs in a community clinic, in order to
deﬁne recruitment and outcome measure parameters for
future research. We undertook spirometry and adminis-
tered validated lung health screening, condition-speciﬁc
and health-related quality of life questionnaires. The
study integrated patient and practitioner group feedback
into the research process, in order to identify the
research priorities of importance to service users and
practitioners and to collaboratively address research study
practicalities and questions arising from the pilot study.
METHODS
Pilot study
Opportunistic sampling methods were employed twice
weekly to recruit participants attending a community
substance misuse clinic, from 3 February 2015 to 14
March 2015. All service users were eligible for inclusion
in the study if they had ever smoked or injected opiates.
This broad inclusion criterion was used to gain an indi-
cation of the prevalence of smoking and injecting behav-
iour in this group. Study recruitment was advertised
through the display of posters within waiting rooms at
the community substance misuse clinic and the distribu-
tion of information leaﬂets to the clinic staff 2 weeks
prior to the study start date. Participants were offered a
£10 supermarket voucher to cover their time commit-
ment and travel costs.
Current National Institute for Health and Care
Excellence (NICE) guidelines,15 16 a recent evaluation
of screening of COPD against the National Screening
Committee (NSC) criteria,17 and two monographs18 19
on recommended outcome measures for asthma and
COPD, respectively, were used to determine screening
processes and condition-speciﬁc outcome measures
for the study. The outcome measures were also
reviewed by an expert panel, which included a con-
sultant psychiatrist in substance misuse, a consultant
respiratory physician, a professor in respiratory medi-
cine and a general practitioner with a special interest
in substance misuse, in order to ensure that the
following measures were research and clinically
appropriate.
1. Study-speciﬁc sociodemographic data questionnaire:
Patient-completed questionnaire used to capture data
on: gender, age, smoking status, current illicit and
prescribed drug use.
2. Health-related quality of life EQ-5D-3L question-
naire:20 A generic measure of health status.
3. The LFQ:21 A patient-completed screening tool, to
be used in primary care settings, to identify
patients who are appropriate for spirometry testing
for airﬂow obstruction.
4. The Asthma control test (ACT):22 The ACT has a
total score up to 25 and assesses the impact and
control of a patient’s asthma over the past 4 weeks.
A score <20 indicates that asthma may not have
been well controlled in the previous 4 weeks.
5. Mini Asthma Quality of Life Questionnaire (Mini—
AQLQ):23 A validated short version of the original
Asthma Quality of Life Questionnaire (AQLQ),24
which measures the impact of asthma on an indivi-
dual’s quality of life and has an overall score, and
four dimensional scores (‘symptoms’; ‘activity’;
‘emotional’; ‘environmental’). The highest
Mini-AQL score of 7.00 indicates no impairment
due to asthma; scores below 7 indicate some
impairment; scores of 1.00 indicates severe impair-
ment and 4.00 indicates a moderate degree of
impairment of quality of life.
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6. Clinical COPD Questionnaire (CCQ):25 A validated
questionnaire used to measure the symptoms and
functional status of patients with COPD.
7. Treatment Outcome Proﬁle (TOP):26 The TOP is
the standard UK outcome measure for substance
misusers in treatment and is completed by clinical
staff with OMUs at appointments. The data from
this questionnaire were collected, with consent, on
a separate visit by a member of the research team
(AP), from the patient clinical record. This infor-
mation was triangulated with the sociodemo-
graphic information collected in order to reduce
participant questionnaire burden relating to add-
itional psychosocial, drug use and physical health
information.
8. Spirometry: Spirometry is used to monitor the
severity of lung conditions and is used as a screen-
ing tool for COPD. Postbronchodilator spirometry
testing was not performed, as dispensing inhaled
medication was beyond the scope of the feasibility
study. NICE guidance was used to categorise
airways obstruction as measured without
bronchodilation.15 16
The overall relevant questionnaire and spirometry
results were discussed with the participant, and depend-
ent on these results, they were advised to attend their
GP for follow-up if there were any abnormalities. A copy
of the individual’s spirometry and questionnaire results,
with an information sheet regarding the study, were
posted to each patient’s GP.
Patient and public involvement
Following study completion, the results of the feasibility
study were also discussed with staff at the community
substance misuse clinic and service users in two separate
patient and public involvement (PPI) events, to facilitate
a discussion about future priorities and research practi-
calities. The service user forum included service users
currently on treatment and undertaking a recovery
rehabilitation programme. The forum for healthcare
professionals included members of staff at the commu-
nity clinic, including a consultant psychiatrist, mental
health nurses and key workers.
RESULTS
The recruitment target of 30 participants was exceeded
within 5 weeks: 36 participants agreed to take part in the
study. The outcome measures administered to each par-
ticipant were dependent on self-reported previous diag-
nosis of asthma or COPD.
Figure 1 summarises participant ﬂow according to self-
reported prior lung disease and completion of screening
questionnaire for those with no prior lung disease diag-
nosis. All participants completed the health-related
quality of life EQ-5D-3L questionnaire and underwent
spirometry. TOP data were collected for 26 participants,
with no data available from the remaining 10 partici-
pants. Of the original 36, 8 participants had a diagnosis
of asthma and completed the asthma-speciﬁc question-
naires (ACT, Mini-AQL), nobody reported a diagnosis of
COPD and the remaining 28 participants had no prior
diagnosis of lung disease and thus completed the ‘case
ﬁnding questionnaire, the LFQ’.
Sample characteristics
In common with the reported predominance of male
OMUs in treatment, there were a greater number of male
(26/36) than female (10/36) participants. The mean age
of participants was 37 years (range 24–53 years; table 1).
Table 2 summarises data collected regarding smoking
status, drug use, inﬂuenza vaccination uptake and
history of respiratory problems. Data provided on
inhaled drug use relate to all history and not solely to
participant’s current inhaled drug use status. Almost all
participants smoked heroin, crack cocaine, tobacco or
cannabis (table 2).
Figure 1 Participant recruitment
and flow chart. COPD, chronic
obstructive pulmonary disease;
TOPs, Treatment Outcome
Profiles.
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Health-related quality of life EQ-5D-3L questionnaire
Findings from the generic health-related quality of life
measure showed that the majority of participants
reported to suffer from anxiety and or/depression, with
58% of the sample reporting having extreme problems
in this instance (table 3). More than half of the partici-
pants also reported having problems with mobility and
pain/discomfort.
Spirometry
All participants had screening spirometry with 5/36
(14%) having forced expiratory volume in 1 s/forced
vital capacity <0.7 (without bronchodilator). Two of
these ﬁve patients had asthma, but without bronchodila-
tion, we cannot determine if there is now a degree of
COPD within this group.
The Treatment Outcome Profile
TOP data could be acquired for 26/36 participants
included in the study. Some issues were identiﬁed with
the consistency of the data, particularly in relation to the
discrepancies between measurements of injecting status.
In this instance, conﬂicting data were collected from
service users in relation to the items measuring current
injecting status, injecting status within the past 30 days
and total number of days injecting in this period. This
suggests the scale may not demonstrate sufﬁcient
internal reliability, and due to such issues, the TOP data
have not been presented in full.
Patients with no prior diagnosis of COPD or asthma
Lung Function Questionnaire
Twenty-eight participants (78%) reported no prior diag-
nosis of COPD or asthma and completed the LFQ. The
mean LFQ score was 15.68 (SD=3.63) and 22 partici-
pants (79%) scored 18 or less, suggesting these partici-
pants had symptoms associated with a risk of developing
COPD (ﬁgure 2).
Participants with prior diagnosis of asthma
Eight of 36 participants self-reported a diagnosis of
asthma. All asthmatics reported signiﬁcant respiratory
symptoms, poor control of their asthma and excessive
daily use of salbutamol (β agonist) inhalers. None of the
participants with asthma was prescribed an inhaled cor-
ticosteroid. The potential impact of comorbid asthma
on service users was also highlighted in the following
free-text response on a questionnaire:
…sometimes I am frightened to go to sleep at night
(because of my breathing)…
Asthma control (ACT)
On average, patients reported a score of 8.86 (SD=2.04)
and all 8 patients scored <13.
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Asthma quality of life results (Mini-AQLQ)
In this study, 5/8 participants scored 4 or less, with an
overall mean score of 3.49 (SD=0.94) reported.
Patient and practitioner feedback
A total of 9 service users and 12 members of staff were
included in the PPI forums. The following themes were
identiﬁed during the meetings:
Recognition of respiratory comorbidity
Service users demonstrated awareness that the inhalation
of heroin, crack cocaine and cannabis could impact on
their breathing and respiratory health. For example, one
service user noted how asthma-related symptoms were
heightened when inhaling heroin, leading to repeated
use of reliever inhalers.
When I’m smoking heroin, it just makes it (asthma) ten
times worse.
Patterns of reliever (blue) and preventer (brown)
inhaler use also supported the proposal that this group
were at risk of developing respiratory health problems.
A lot of them have got asthma pumps, nearly everyone,
but not the brown ones.
The potential danger of inhaling the additive agents
often mixed with heroin was also recognised as an issue,
as was the storage of the substance, with service users
highlighting the fact that the heroin they inhaled was
often stored in used fuel containers.
The dealers hide the heroin in petrol or diesel contain-
ers so it always stinks of petrol/diesel when you inhale it.
The impact of poor housing conditions was also recog-
nised by service users as a potential contributing factor
to poor respiratory health.
Table 2 Self-reported smoking status, drug use, influenza vaccination uptake and respiratory problems (n=36)
Smoking status
Current smoker
n (%)
Ex-smoker
n (%)
Never smoked
n (%)
35 (97) 1 (3) 0 (0)
Years smoked Mean (SD) Range
24 (7.60) 2–40
Cigarettes smoked per day Mean (SD) Range
15 (10.60) 0–50
Inhaled drug use Heroin n (%) Cocaine n (%) Cannabis n (%)
34 (94) 33 (92) 31 (86)
Influenza vaccination history (previous
2 years)
Received influenza
vaccination
n (%)
Failed to receive influenza
vaccination
n (%)
9 (25) 27 (75)
Table 3 Self-reported health status (n=36)
Mobility Self-care Usual activities Pain/discomfort Anxiety/depression
No problems
n (%)
13 (36) 25 (69) 22 (61) 14 (39) 5 (14)
Some problems
n (%)
23 (64) 11 (31) 14 (39) 17 (47) 10 (28)
Extreme problems
n (%)
0 (0) 0 (0) 0 (0) 5 (14) 21 (58)
Figure 2 LFQ scores from participants with no prior
diagnosis of COPD or asthma (n=28). COPD, chronic
obstructive pulmonary disease; LFQ, Lung Function
Questionnaire.
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A lot of people with addiction problems as well, they
have housing problems, and they get put in all sorts of
places. Rising damp, spores, yeah? Gets in your lungs.
An awareness of the burden of respiratory health was
also recognised by healthcare professionals, with an
overall perception that more focus is required on
respiratory health and whole patient care in general.
Barriers to accessing to health services
The need for further research into the screening of
OMUs in specialist settings was further highlighted by
the barriers to accessing primary healthcare services for
service users. With regards to their lifestyle, service users
highlighted frequent re-locating as a key barrier to acces-
sing care, the attitudes of healthcare professionals and
the current operating systems in place. With regard to
their lifestyle, service users highlighted frequent relocat-
ing as a key barrier to accessing care:
Yeah, a lot of us have that in common, move a lot, 2
doctors a year, for the last 5 years… at least.
Several service users described dismissive attitudes of
healthcare practitioners, leading to reluctance to access
such services.
I went to the doctor, um, about my heart, about this
problem here, about breathing…and they said oh do you
inject heroin, I’m like no, and I was actually like clean of
all opiates, for over 10 months, and so I said that but of
course, they see your history and they don’t believe you.
Finally staff members reﬂected on the difﬁculties
service users experience in accessing healthcare services,
with suggestions that service users often found the tele-
phone booking systems for GP services difﬁcult to use
and that the narrow time frame available to book
appointments discouraged service users from accessing
primary care services. It was once again proposed that
such systems formed a considerable barrier to care when
combined with the desire for an instant appointment
and the chaotic lifestyle associated with OMUs who
accessed services.
Willingness to use screening
With regard to the potential beneﬁt of respiratory
health screening programmes, service users implied a
willingness to use such services in substance misuse
clinics and pharmacies and to further participate in
further research in this ﬁeld:
Yes people do want to think about improving their long
term health and when healthcare workers offer ways to
help them do this, it is appreciated…
Some concerns were raised over the capacity of such
settings to offer additional care:
Queues too big in the big pharmacies, but going to a
small pharmacy, I think they might have the time.
Service users also stated that the use of incentives was
not a necessary requirement to encourage participation
in research, as the spirometry and lung questionnaires
were not invasive or too time consuming. The detrimen-
tal impact of incentivising participants was also noted by
the staff. In this instance, it was suggested that examples
of patients self-referring in order to receive the £10
voucher for taking part could cause a disruption to the
service. The high number of potential participants,
which exceeded expectations, highlighted the potential
widespread acceptability of such screening services.
However, it also demonstrated the potential strain placed
on resources in community settings and the potential
negative impact this could have on the patient’s experi-
ence of care, if appropriate resource planning is not
undertaken. For example, the staff reported that
although they were happy to facilitate the research,
limited availability of space hindered recruitment.
DISCUSSION
Findings from the current study suggest that it is feasible
to screen for respiratory health problems in a clinic
population of OMUs. These screening programmes
could lead to a better understanding of the prevalence
of the issue, the contributing factors and help improve
access to proactive respiratory healthcare for OMUs.
The acceptability of respiratory screening in the OMU
population is demonstrated through the high rates of
participation within a 5-week period and the wealth of
data collected from participants. For example, service
users were willing to complete a survey including four
validated scales relating to respiratory health and quality
of life and items measuring sociodemographic status
and all participants were willing to undergo spirometry
testing during the study. This willingness to undertake
respiratory screening in routine settings mirrors previous
ﬁndings from a study looking at COPD screening over
three CRI centres, in which 129 heroin users were
recruited over a 6-month period.10
Support for the feasibility of implementing a respira-
tory screening programme in substance misuse clinics
was evident from the feedback presented at two separate
PPI events including both healthcare professionals and
service users. The discussion taking place at these events
highlighted the added value of integrating practitioner
and service user feedback into the research process. In
addition to highlighting the importance of whole
patient care in OMUs and the willingness and capacity
available to deliver screening services, these forums also
offered solutions on how to overcome barriers relating
to practical limitations associated with research in these
settings and to service access. These barriers to accessing
care for this population, relating to structural issues and
the stigma of addiction, have also been reported in the
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wider literature.27 28 In this instance, it has been sug-
gested that the use of appointment reminders and a
degree of ﬂexibility over appointments could improve
access to care and treatment retention. Feedback from
service users also provided further evidence of poor
respiratory health in OMUs as a result of substance
misuse and associated environmental factors, such as
poor housing conditions. These concerns over the
impact of poor housing on respiratory health are sub-
stantiated by ﬁndings suggesting factors such as damp
and mould are determinants of developing asthma.29
Evidence of poor asthma control, in relation to the
lack of awareness and use of preventer inhalers, was also
noted from the PPI forums. Poor asthma control poten-
tially puts this population at high risk of acute, severe
exacerbations; chronic asthma and progression to
COPD, with a recent national report suggesting that
underprescription of reliever inhalers were evident in
80% of all asthma deaths in 2014. Evidence of poor
asthma control in this group is also supported from the
initial ACT scores reported in this group. Results from
the LFQ and spirometry testing also suggested evidence
of a respiratory health burden in OMUs. For example,
LFQ scores suggested that 79% of the participants had
symptoms associated with a risk of developing COPD
and spirometry scores indicated 14% had potential
obstructive lung disease. This potential burden once
again adds further support to previous ﬁndings from the
screening of heroin users across CRI services in
Liverpool, in which overall, 61% of the sample were
identiﬁed as showing symptoms of airway disease, with
28% of participants identiﬁed as displaying symptoms
consistent with COPD.10 In contrast to this previous
study, the current project assessed the feasibility of tar-
geting settings solely designed for substance misusers.
Furthermore, through using the ACT, quality of life mea-
sures and integrating PPI feedback, the current study
provided a more in-depth understanding of the some of
the implicating factors of poor respiratory health in this
population, such as the barriers to respiratory health-
care, and how this impacts on this population’s overall
physical and mental well-being. The current study also
assessed the feasibility of using TOPs data as a routine
database outcome measure for research relating to
comorbidities and opiate misuse. In this instance, some
issues were reported in relation to missing data and the
internal reliability of the scale. However, previous analysis
suggests that the TOPs data are both valid and reliable.26
It is therefore suggested that certain items included in
the TOP could be used in future research, with the
impact of missing data potentially reduced if integrated
into the initial data collected by the study team.
A further factor to take into consideration is the
impact of polydrug use on the respiratory health of
OMUs. For example, ﬁndings from the current study
showed that the majority of service users had also
experience of inhaling cocaine and cannabis, with pre-
vious studies demonstrating the inhalation of such
substances to have a caustic effect on the lungs.30 31 In
addition to this, smoking prevalence is also especially
high in this pilot sample, with all participants reporting
to have smoked tobacco, and only one participant no
longer a current smoker. These ﬁgures exceeded preva-
lence rates reported in a recent systematic review of
smoking prevalence in addiction treatment pro-
grammes, which were 85.1% in OMUs.32 It is clear that
such factors as tobacco smoking and polydrug use need
to be controlled for in future screening studies in
order to gain a better understanding of the overlap-
ping effects in this population.
A number of limitations with the current study have
to be noted. For example, due to the small sample
size and lack of statistical analysis, the ﬁndings from
this feasibility study in relation to the prevalence of
poor respiratory health in this population have to be
approached with caution. We were not able to collect
data on non-participants and thus, although the provi-
sion of vouchers encouraged all service users to
attend regardless of whether they had experienced
respiratory symptoms or not, participants in this study
may have differed from the general clinic population.
Conversely, it could also be suggested that the sample
could be biased by service users with poor respiratory
health being more likely to select to take part in the
study. The study may also have differed from the
general clinic population with regard to the age. For
example, although the average age of 37 years was
reﬂective of recent national data from the National
Drug Treatment Monitoring System, there was an
under-representation of participants over the age of
40 years.33 For example, only 10% were above 40 years
in the current study, compared with 43% reported in
national data on this population. A further limitation
is the ongoing debate over the appropriateness of
such tools as the LFQ due to concerns over the
number of false positives when used as a screening
tool.17 There is also debate regarding the GOLD estab-
lished parameters for diagnosis of COPD using spirometry
testing results, with Cartwright also suggesting that there is
evidence of misdiagnosis in older populations. For such
reasons, Cartwright17 concluded to recommend against
population screening for COPD and reported concerns
over the capacity in primary and secondary care to imple-
ment such programmes. However, it has been noted that
cost-effective evidence is available for the opportunistic
case ﬁnding of respiratory health issues in patients with at
higher risk of disease development, such as smokers and
individuals aged over 35 years.34 In this instance, it was
reported that the potential cost per life year gained is
£713.16 and the potential cost per quality-adjusted life
year gained is £814.56. Therefore, it is suggested that tar-
geted programmes would be beneﬁcial to other potential
high-risk groups, such as OMUs. This current study has
suggested that settings such as community substance
misuse clinics hold sufﬁcient capacity to implement such
programmes.
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CONCLUSIONS
Through the integration of pilot and feasibility work
and staff/patient engagement, the current study suggests
that it is identiﬁed as an important topic to patients and
practitioners and feasible to undertake the respiratory
health screening of OMUs in a community substance
misuse clinic. The relatively high prevalence of respiratory
symptoms, as measured by the LFQ and abnormal spir-
ometry make a case for a larger research screening pro-
gramme for respiratory health burden in these settings,
including spirometry with reversibility testing order to
establish the population prevalence of respiratory health
problems such as asthma and COPD in OMUs.
In line with this proposal, work is currently being
undertaken by a UK Academic Health Sciences Network
sponsored study team looking at whether OMUs with
comorbid asthma are at a higher risk of poorly controlled
asthma when compared with a population of non-OMUs
with asthma. It is also proposed that future research
should investigate place and mode of delivery of proactive
respiratory healthcare to a high-risk group of OMUs with
comorbid respiratory health problems such as asthma.
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